Bachofen M, Gallati H, Pracht I, Bock H, Landmann J, Thiel G
Division of Nephrology, Department of Internal Medicine and Surgery, University of Basel, Basel, Switzerland.
Transpl Int. 1992;5 Suppl 1:S473-5. doi: 10.1007/978-3-642-77423-2_138.
Comparing OKT3 and antithymocyte globulin (ATG) in a prospective study, the dosage difference in regard to body weight (ATG: dependent on body weight/OKT3: independent) does not introduce any obvious source of mistake concerning clinical effectiveness or side effects. One explanation for the lack of influence of body weight may be the high effectiveness of 5 mg of OKT3, reaching a maximal effect even with lower plasma levels in heavier patients. We wonder, therefore, whether the OKT3 dosage could be lowered.
在一项前瞻性研究中比较OKT3和抗胸腺细胞球蛋白（ATG）时，关于体重的剂量差异（ATG：依赖于体重/OKT3：独立于体重）在临床疗效或副作用方面并未引入任何明显的错误来源。体重缺乏影响的一种解释可能是5毫克OKT3的高效性，即使在体重较重的患者中血浆水平较低时也能达到最大效果。因此，我们想知道OKT3的剂量是否可以降低。
